Bente Gammelgaard* and Lars Bendahl
Department of Analytical Chemistry, The Danish University of Pharmaceutical Sciences, Universitetsparken 2, DK-2100 Copenhagen, Denmark. E-mail: bg@dfh.dk; Fax: +45 3530 6010
First published on 26th September 2003
Human urine samples were analysed by a reversed-phase chromatographic system and an ion-pair chromatographic system. The chromatographic system was connected to the ICP-MS either by a microconcentric nebulizer (MCN) in combination with a cyclonic spraychamber or by a modified direct injection nebulizer (MDIN). The sensitivity of the latter was better than the sensitivity of the MCN, which on the other hand was more robust for the analysis of samples with high concentrations of dissolved solids. Urine sample composition did not seem to change when urine was exposed to evaporation under nitrogen at ambient temperature and methanol extraction. A pre-concentration factor of 10 was achieved with this procedure. On occasions when a pre-concentration factor of 100 was obtained by lyophilsation and methanol extraction, at least 10 selenium compounds were separated in the urine sample. Urine samples were collected from two healthy volunteers who had been supplied with 1000 µg and 2000 µg of selenium, respectively, in the form of selenized yeast. When samples were spiked with 8 different standards, only two standards co-eluted with compounds in urine in both chromatographic systems: the major urinary metabolite Se-methyl-N-acetylgalactosamine and Se-methyl-N-acetylglucosamine. The presence of Se-methyl-N-acetylglucosamine in urine was verified by co-migration with the standard in capillary electrophoresis after fractionation by preparative reversed-phase chromatography. Se-methyl-N-acetylglucosamine is only a minor metabolite as its concentration was less than 2% of the concentration of Se-methyl-N-acetylgalactosamine. The presence of this metabolite in urine has, to our knowledge, not been suggested before. Trimethylselenonium, selenomethionine, Se-methylselenocysteine, Se-methylselenomethionine and selenocystamine were not detected in these samples.
Selenium deficiency causes various adverse health effects2 and in recent years the element has gained increasing interest owing to its possible cancer protective effects.3 Results of experiments on the cancer protective effect of monomethylated selenium compounds such as selenobetaine, Se-methylselenocysteine and methylseleninic acid suggest that formation of a monomethylated selenium metabolite is important for cancer chemoprevention.4–6
Fig. 1 Model of selenium metabolism modified from the original model by Ip5 and supplemented with the latest results of the work from the group of Suzuki.13 GS-: Glutathion conjugate. |
The metabolism of inorganic selenium in sub-toxic doses in rats has been thoroughly described by Suzuki and co-workers on the basis of administration of 82Se-enriched selenite and selenate and subsequent determination of the 82Se level in organs and body fluids by size exclusion chromatography and ICP-MS detection.9 Intravenously injected selenite was selectively taken up by the red blood cells (RBC)10 and reduced by glutathion (GSH) to selenide. Selenide was transported to the liver, where it was incorporated into selenoprotein P, re-excreted to the bloodstream and transferred to the kidneys, where it was degraded and used for synthesis of extra-cellular glutathion peroxidase.9 Contrary to selenite, selenate was not taken up by RBCs but was retained in the bloodstream until it entered the liver or was excreted directly in urine. The metabolic products of selenite and selenate were not distinguishable.11 The selenium in liver was distributed between two compounds, the major urinary metabolite Se-methyl-N-acetylgalactosamine12 and a compound in which the methyl group on selenium was exchanged with glutathione. It was suggested that this compound was a precursor of the major urinary metabolite.13 This pathway is shown in Fig. 1 as the pathway for non-toxic doses. The metabolism of selenium in humans is presumed to follow the same ways.
Selenium compound | Analytical techniquea | Reference |
---|---|---|
a IPC: Ion-pair chromatography; RPC: reversed-phase chromatography; CEC: cation exchange chromatography; AEC: anion exchange chromatography; MS: mass spectrometry; HG: hydride generation; MIP: microwave induced plasma. | ||
Trimethylselenonium | IPC-ICP-MS | 14–16 |
RPC-ICP-MS | 16–18 | |
CEC-ICP-MS | 19,20 | |
Selenite | IPC-ICP-MS | 14 |
RPC-ICP-MS | 21 | |
AEC-ICP-MS | 22 | |
AEC-HG-N2-MIP-MS | 23 | |
Selenomethionine | CEC-ICP-MS, CE-ICP-MS | 19 |
RPC-ICP-MS, tandem MS/MS | 24 | |
IPC-ICP-MS | 18 | |
Selenocystamine | RPC-ICP-MS, tandem MS/MS | 24 |
Se-methyl-N-acetylgalactosamine | RPC-ICP-MS, MS/MS | 25 |
In most of the studies, the identities of the selenium compounds were suggested on the basis of co-elution with standards. However, recently some metabolites have been identified by electrospray ionisation mass spectrometry (ESI-MS). Selenomethionine and selenocystamine were identified by tandem mass spectrometry in urine from an adult male who had been supplemented with a single dose of 400 µg of selenomethionine. The multiple reaction monitoring mode, in which one or more transitions of precursor to product ions are monitored in tandem, was used for the identification.24 The major metabolite in human urine was identified by atmospheric pressure chemical ionisation mass spectrometry (APCI-MS) in a human urine pool obtained from 6 male volunteers supplemented with 200 µg of selenium-enriched yeast a day for 1 week. This metabolite was Se-methyl-N-acetylgalactosamine25—the same metabolite as the one previously obtained from rats after supplementation with selenite.12
Apart from the selenium compounds listed in Table 1, the presence of selenocholine and selenourea in urine has been cited in reviews. However, going into the original references, it appears that standards of these species may have been separated in a urine matrix, but they were not identified in the original urine samples.26
Most of the identifications represented in Table 1 were performed on untreated samples that were only diluted and or filtrated.14–16,20–22,27,28 Others used solid-phase extraction on C18 cartridges to remove uncharged organic compounds,17 but also more aggressive procedures as crown ether extraction has been applied to remove potassium and sodium from the samples.19
Pre-concentration prior to MS-identification includes lyophilisation followed by chromatographic fractionation,24 incubation with urease at 45 °C followed by evaporation and extraction with cold methanol, prior to chromatographic fractionation,12 and solid phase extraction, followed by chromatographic fractionation on reversed phase and size exclusion columns.25 In a previous study we observed that the major metabolite decomposed into another compound within 24 h at ambient temperature,18 hence it is crucial for identification studies that the analytical procedures preserve the original selenium compounds.
The aim of this study was to develop analytical procedures for separation of selenium compounds in human urine and to investigate if the sample preparation procedures usually applied for pre-concentration of samples change the sample composition. A secondary aim was to identify the compounds in urine by co-elution with available standards with the future aim of identifying new compounds by ESI- or APCI-MS.
The flow rate was 200 µl min−1 and the sample injection volume was 12 µl when 2 mm id columns were used. When 1 mm id columns were used the flow rate was 50 µl min−1 and the sample injection volume was 3 µl.
Reversed phase chromatography. The columns were two Luna C18(2), 100 mm × 2 mm id, 3 µm particle size, in series (Phenomenex, Aschaltenburg, Germany). The eluent was 200 mM ammonium acetate + 5% methanol.
Ion-pair chromatography. The column was a Luna C8(2), 100 mm × 2 mm id, or a 100 mm × 1 mm id, 3 µm particle size (Phenomenex). The eluent was 0.2% heptafluorobutanoic acid (HFBA) + 20% or 30% methanol.
The chromatographic system was coupled to the ICP-MS system via 175 µm id PEEK tubing (Upchurch Scientific, Oak Harbor, WA, USA).
Buffer: 25 mM borate diluted from “buffer pH 9.3 for HPCE” (Agilent Technologies); sheath liquid: 5% acetic acid in 0.67% nitric acid, flow rate 10 µl min−1.
The ICP-MS was a PE SCIEX ELAN 6000 (PerkinElmer, Norwalk, CT, USA equipped with a MicroMist AR30-1-F02 glass concentric nebulizer and a cyclonic spray chamber (Glass Expansion, Romainmotier, Switzerland). The spray chamber was cooled to −4 °C when the eluent contained more than 5% methanol. A direct injection nebulizer that has previously been described29 was used for interfacing CE and 1 mm id columns.
Sampler and skimmer cones were of platinum. The plasma and auxiliary argon flow rates were 14 and 1.2 L min−1, respectively. The nebulization argon gas flow rate was 1.025 L min−1 for the microconcentric nebulizer and 0.2 L min−1 for the direct injection nebulizer. The rf power was 1300 W (CE) and 1425 W.
The data acquisition parameters were: dwell time, 300 ms; sweeps per reading, 1; readings per replicate, 750/1500 (CE).
The 77Se, 78Se and 82Se isotopes were monitored. To achieve maximum sensitivity, the instrument was optimised with respect to the nebulizer gas flow rate, ion lens voltage and rf power when aspirating each eluent spiked with selenite.
Peak heights and peak areas were calculated by Turbochrom (PerkinElmer).
Stock standard solutions of 10 mg Se L−1 were prepared in water from selenomethionine (Sigma), Se-methylselenocysteine (Sigma), selenocystamine (Sigma), selenoethionine (Sigma), trimethylselenonium iodide (synthesized according to ref. 30), Se-methylselenomethionine (synthesized according to ref. 31), Se-methyl-N-acetylglucosamine (synthesized in a modified version according to ref. 12) and Se-methyl-N-acetylgalactosamine (synthesized at the Department of Medical Chemistry, The Danish University of Pharmaceutical Sciences). The stock standard solutions were standardized against a 1.001 g Se L−1 PE pure atomic spectroscopy standard (PerkinElmer). Working standards were prepared daily in water.
A: 1000 µl of urine was evaporated in a stream of nitrogen at ambient temperature and reconstituted in 100 µl of eluent.
B: 1000 µl of urine was evaporated in a stream of nitrogen at ambient temperature and extracted with 1000 µl of methanol in an ultrasonic bath for 5 min. The extract was centrifuged at 14000 rpm for 5 min and the supernatant evaporated to dryness at ambient temperature and reconstituted in 100 µl of eluent.
The sediment from the centrifugation was reconstituted in 100 µl of eluent and analysed.
C: 100 ml of urine was lyophilised and extracted with 10 ml of methanol by sonication for 5 min. The extract was centrifuged 5300 rpm for 5 min and the supernatant was evaporated to dryness in a stream of nitrogen at ambient temperature and reconstituted in 1 ml of eluent.
Urine samples analysed in the HFBA system were adjusted to pH 2 by addition of concentrated HFBA.
Turbid samples were filtered through a 0.45 µm cellulose membrane (Cromacol Ltd., Trumbull, CT, USA) prior to analysis.
The 77Se, 78Se and 82Se isotopes were monitored simultaneously. The S/N ratio for 78Se was about half the value of the S/N ratio for 77Se and 82Se when using the MCN, so 82Se was chosen for this system. Using the MDIN, the S/N ratio was better for 78Se than for 77Se and 82Se and this isotope was chosen for the direct injection system.
Chromatograms of selections of the 8 aqueous selenium standards trimethylselenonium (TMSe), Se-methylselenocysteine (MeSeCys), Se-methylselenomethionine (MeSeMet), selenocystamine (SeCA), selenomethionine (SeMet), Se-methyl-N-acetylgalactosamine (SeGal), Se-methyl-N-acetylglucosamine (SeGlu) and selenoethionine (SeEt), each in a concentration of 10 µg L−1, in the different chromatographic systems coupled via the different interfaces, are shown in Fig. 2. It appears that the signal to noise ratio of the MDIN was superior to the MCN in combination with the cyclonic spraychamber. Furthermore, the monitoring of 78Se with the more favourable signal to noise ratio using the direct injection nebulizer further improved the sensitivity as the abundance of this isotope is 23.8% compared with 8.7% for 82Se. The detection limits calculated as the concentration that would give a signal equivalent to 3 times the peak-to-peak noise at the baseline in each system are given in Table 2. These detection limits were calculated for different nebulizers in combination with columns with different inner diameters operated at different flow rates. Hence, the detection limits represent the total chromatographic system including the interface. These detection limits are in accordance with previously reported values, the majority being below 2 µg L−1.14–18,20–23,27,28
Fig. 2 Chromatograms of aqueous standards in concentrations of 10 µg Se L−1 each. A, Reversed-phase chromatography, eluent 200 mM ammonium acetate + 5% methanol, nebulizer MCN. B, Ion-pair chromatography, eluent 0.2% HFBA + 30% methanol, nebulizer MCN. C, Ion-pair chromatography, eluent 0.2% HFBA + 20% methanol, nebulizer MDIN. |
When large numbers of concentrated urine samples were analysed, the micro-bore column used in combination with the MDIN quickly deteriorated and the tip of the nebulizer often clogged due to salt crystals. Hence, the MCN in combination with the 2 mm inner diameter columns was chosen for some applications in defiance of its lower sensitivity, as it was more robust for analysis of large numbers of concentrated urine samples.
None of the chromatographic systems were capable of separating all the available standards in a reasonable time. Only in the reversed phase system were the selenosugars SeGal and SeGlu separated satisfactorily. However, in this system TMSe, and other charged compounds, were not retained. The HFBA system retained TMSe, while the uncharged selenosugars were only weakly retained and hardly separated. In the HFBA system containing 20% methanol, the retention times of SeCA and SeEt were 22 min and 33 min, respectively, and resulted in intensive peak broadening. Hence, 30% methanol was used when these compounds were analysed.
Some of the standards were chosen as they have previously been identified in the human urine samples: TMSe, SeCA, SeMet and SeGal (Table 1). SeGlu was chosen as in our previous experiments with fractionation and pre-concentration of urine for APCI-MS identification of SeGal, a compound which co-eluted with SeGlu appeared. Hence, it would be interesting if this compound could be identified in urine. SeEt was included as a possible internal standard.
Fig. 3 Chromatograms of urine samples after different sample pre-concentration procedures. Reversed phase chromatography: eluent 200 mM ammonium acetate + 5% methanol, nebulizer MCN. A: Undiluted urine sample, black line; sample spiked with standards in concentrations of 20 µg Se L−1 each, grey line. B: Evaporated urine sample (pre-concentrated 10 times), black line; sample spiked with standards in concentrations of 100 µg Se L−1 each, grey line. C: Methanol extracted urine sample (pre-concentrated 10 times), black line; sample spiked with standards in concentrations of 100 µg Se L−1 each, grey line. D: Extraction sediment, black line; sediment spiked with standards in concentrations of 100 µg Se L−1 each, grey line. E: Lyophilised urine sample (pre-concentrated 100 times). |
Fig. 3D shows an analysis of the sediment from the centrifugation in the methanol extractions. It appears that the majority of the selenium was extracted with methanol: the total loss of SeGal in the extraction was less than 5%.
Fig. 3E shows a volume of 100 ml of the same urine that was lyophilised, methanol extracted and reconstituted in 1 ml of eluent, corresponding to a concentration factor of 100. It appears that about 10 selenium compounds were more or less separated. Spiking with standards only showed co-elution with SeGal and SeGlu and the chromatography was poor as this sample contained approximately 50% dissolved solids. Hence, pre-concentration in this scale is only suitable and necessary for fractionation of samples by preparative chromatography prior to MS identification. However, the shapes of the chromatograms from the different pre-concentration procedures look very similar, which indicates that the selenium compounds in the original undiluted sample were not changed noticeably by the gentle procedures of evaporation under nitrogen at ambient temperature, lyophilisation, or methanol extraction. Hence, these procedures could be used for pre-concentration of samples prior to identification.
When the samples were analysed in the ion-pair system, the absence of TMSe and MeSeCys was confirmed in the undiluted as well as the methanol extracted sample. This is shown in Fig. 4A and 4B. Thus, only SeGal and SeGlu co-eluted with compounds in urine in both systems.
Fig. 4 Chromatograms of urine samples. Ion-pair chromatography, eluent 0.2% HFBA + 20% methanol, nebulizer MDIN. A: Undiluted urine sample, black line; sample spiked with standards in concentrations of 50 µg Se L−1 each, grey line. B: Methanol extracted urine sample, black line; sample spiked with standards in concentrations of 100 µg Se L−1 each, grey line. |
One unidentified compound with a retention time of 4 min was observed in the reversed phase system. The retention times of aqueous standards were almost identical to the retention times in spiked urine samples. The urine sample in Fig. 3A and B was spiked with SeCA, but no increase in peak size was observed at the retention time of SeCA. It was later observed that adding SeCA to urine samples prior to analysis in the reversed phase system resulted in an indefinable peak.
To examine if SeEt or SeCA were present in urine, the undiluted urine sample, as well as the methanol extract, was analysed in an ion-pair system containing 30% methanol, which was capable of separating aqueous standards of these compounds, Fig. 2B. No co-elution was observed with urine compounds in this system (data not shown). Hence, the presence of SeEt and SeCA in this sample was excluded.
Fig. 5 Identification of SeGlu. A: Preparative chromatography of pre-concentrated sample, black line; superimposed with 100 µg Se L−1 standard addition of SeGal and SeGlu, grey line; fractions collected, shaded area. B. Electropherogram of SeGal and SeGlu standards in concentrations of 1 mg Se L−1. C: Electropherogram of collected fractions from A. D: Collected fractions spiked with 1 mg Se L−1 SeGal and SeGlu. |
The presence of SeGlu in urine has, to our knowledge, not been reported before. This could be due to the lack of commercially available standards or due to the very low concentration of this compound in urine. SeGlu is only a minor metabolite: the concentration in this sample was less than 2% of the SeGal concentration and the metabolite was only detectable after consumption of relatively large amounts of selenium.
From our previous experiments it was known that SeGal was partly decomposed in 0.1% HFBA within 24 h, probably owing to the acidic pH adjustment of the samples with the purpose of converting amino groups in selenium compounds to cationic species prior to analysis in the anionic ion-pair medium.18 Hence, this chromatographic system is not suitable for long series of analyses as the samples decompose in the autosampler. Also decomposition of untreated urine samples was observed in this study. Fig. 6 shows chromatograms of a urine sample kept at ambient temperature for 3 d. It appears from both chromatograms that new unidentified selenium containing compounds with a retention time of about 6.5 min in the reversed phase system, Fig. 6A, and 11 min in the ion-pair system, Fig. 6B, were formed from degradation of SeGal.
Fig. 6 Chromatograms of urine sample after storage for 3 d at ambient temperature. A: Eluent 200 mM ammonium acetate + 5% methanol, nebulizer MCN. B: Eluent 0.2% HFBA + 20% methanol, nebulizer MDIN. |
When standards were added to urine and analysed in the reversed phase system both immediately and after 3 days it appeared that TMSe, MeSeCys, MeSeMet and SeEt were stable in urine samples for this time span at ambient temperature. It was rather surprising that MeSeMet was stable in urine as this compound is very unstable in aqueous solution. The concentrations of SeGal, SeGlu and SeMet were more or less halved. SeCA showed an indefinable peak from the beginning. These findings are in accordance with findings by others. Loss of SeMet in urine stored at 25 °C, together with appearance of new unidentified compounds, have been reported.32,33 Also, immediate decomposition of SeCA after its addition to urine has been reported.15
To determine whether the selenium compounds would be recovered from the method of freeze drying combined with methanol extraction in preparation for identification with MS, urine samples were spiked with selected standards and extracted. TMSe, SeMet, SeGal and SeGlu were all extracted into methanol. SeCA was also added to the sample but the peak with a retention time of 4 min that co-eluted with SeCA (Figs. 2A and 3A) did not increase. Hence, the unidentified compound was extracted and SeCA was not.
These results show that the identities of the compounds have to be known before the stability can be examined. Regarding quantitative determinations, further stability studies and recovery experiments at different storage temperatures should be performed on the relevant standards. These are initiated in our laboratory.
Fig. 7 Chromatograms of methanol extracted urine samples collected before and after ingestion of 77Se-labelled yeast. A: 77Se before ingestion of 77Se, grey line; 82Se before ingestion of 77Se-labelled yeast, lower black line; 77Se after ingestion of 77Se-labelled yeast, upper black line (full-size peak height of SeGal, 400000 cps). B: Urine sample spiked with selected standards. 77Se after ingestion of 77Se-labelled yeast, grey line; 82Se after spiking with standards in concentrations of 100 µg Se L−1, black line. |
In conclusion, various separation systems can be combined to identify selenium compounds in urine as one system rarely has the resolving power to separate all compounds. Evaporation of urine samples at ambient temperature, lyophilisation and methanol extraction do not change urine samples and can be used to pre-concentrate samples for identification. Two metabolites were identified in the urine samples, the major metabolite Se-methyl-N-acetylgalactosamin and a novel metabolite attributed to Se-methyl-N-acetylglucosamine by orthogonal separation techniques.
This journal is © The Royal Society of Chemistry 2004 |